GlaxoSmithKline Acquires Next-Generation Antibody Company Domantis
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 79 (Table of Contents)
Published: 1 Jan-2007
DOI: 10.3833/pdr.v2007.i79.404 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Another of the UK's most promising biotech companies has become the target of big pharma, with GlaxoSmithKline entering into an agreement to acquire privately held Domantis for #8356;230 M (US$454 M) in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS